LGALS3, galectin 3, 3958

N. diseases: 557; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE We have previously shown that silencing galectin-3 in metastatic melanoma cells reduces tumor growth and metastasis. 22986745 2012
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE We find that metastatic cancer cells exhibit elevated presentation of the oncofetal galectin-3 carbohydrate ligand, the Thomsen-Friedenreich antigen, on their surfaces as a result of altered C2GnT2 and St6GalNAc4 glycosyltransferase activity that inhibits further glycosylation of this carbohydrate motif and promotes metastasis. 25421439 2015
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE We conclude that CD146/MCAM interactions with circulating galectin-3 may have an important influence on cancer progression and metastasis. 28364041 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE This study provides direct evidence that galectin 3 plays an important role in colon cancer metastasis. 9679034 1998
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE This study investigates the hypothesis that PNA appearance in the circulation after peanut ingestion may mimic the actions of endogenous TF-binding human galectin-3 in metastasis promotion. 25326505 2014
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype BEFREE This study demonstrated that the galectin-3 expression was associated with tumor vascular invasion and metastasis, suggesting that galectin-3 plays a critical role in tumor progression via an invasive mechanism but not via proliferation in breast cancer. 23090139 2013
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE This review aims to describe recent progress in understanding the role of galectin-3 in cancer biology, with emphasis on bladder tumor progression and metastasis. 26429330 2015
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE This may have important implications for understanding the role of galectin-3 in colon cancer metastasis. 12198708 2002
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE These studies define a galectin-3/phospho-caveolin-1/RhoA signaling module that mediates integrin signaling downstream of growth factor activation, leading to actin and matrix remodeling and tumor cell migration in metastatic cancer cells. 23657817 2013
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE These results provide the first direct evidence for a Mac-2-binding protein function and suggest that it may play a role in tumor cell embolization during metastasis through interaction with galectin-3. 8813152 1996
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype BEFREE These results may lead to the development of a therapeutic modality aiming at abrogating Gal-3 translocation into the nucleus and thus hampering its activity during cancer progression and metastasis. 17047062 2006
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE These results demonstrate that carbohydrate-mediated, metastasis-associated tumor cell adhesion could be inhibited efficiently with short synthetic peptides which do not mimic naturally occurring glycoepitopes yet bind to the galectin-3 carbohydrate recognition domain with high affinity and specificity. 15528216 2005
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE These findings suggest LGALS3BP and galectin-3 as new targets to treat metastatic cancer and fibrosing diseases. 26136428 2015
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Therefore, targeting HMMR along with galectin-3 and C/EBPβ complex, could be a potential treatment strategy for inhibiting gastric cancer progression and metastasis. 31822520 2020
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE The objective of the present study was to determine whether the absence of G3 immunostaining in preoperative FNA samples is associated with favorable clinicopathological parameters, including lymph node (LN) metastasis, in papillary thyroid carcinoma (PTC). 22892040 2012
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype BEFREE The mean ratio of colon cancer HLBP31 mRNA to adjacent normal mucosa HLBP31 mRNA was twofold lower in primary tumors of patients with metastases (0.3 +/- 0.2 SD) than in primary tumors of patients free of metastatic lesions (0.6 +/- 0.2 SD). 1386115 1992
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype LHGDN The expression of Gal-3 was higher in thin primary melanoma lesions than in benign pigmented skin lesions or metastases and seemed to correlate inversely with the aggressiveness as estimated by the Breslow index which is recognized as the main prognostic factor in melanoma. 15645276 2005
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype BEFREE The clinical importance of serum galectin-3 levels in breast cancer patients with and without metastasis. 30249872 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE The aim of this study was to evaluate if the immunohistochemical markers cyclin D1 or galectin-3 might indicate the presence of metastatic disease in patients with PMC at the time of diagnosis. 17906980 2008
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype LHGDN The aim of this study was to evaluate if the immunohistochemical markers cyclin D1 or galectin-3 might indicate the presence of metastatic disease in patients with PMC at the time of diagnosis. 17906980 2008
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype BEFREE The galactoside-binding protein galectin-3 is commonly overexpressed by cancer cells and promotes cancer progression and metastasis. 31604080 2020
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Taken together, our results suggest a new molecular mechanism of galectin-3-mediated cell adhesion in cancer metastasis. 30171204 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Since MVMp is an oncotropic virus, and galectin-3 is a multifunctional protein implicated in cancer metastasis, we hypothesized that galectin-3 and Mgat5, the Golgi enzyme that synthesizes high-affinity glycan ligands of galectin-3, might play a role in MVMp infection. 25768892 2015
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Poly-N-acetyl-lactosamine (polyLacNAc) substituted N-oligosaccharides on melanoma cell surface glycoproteins promote lung specific metastasis via galectin-3 by facilitating their arrest and extravasation. 28875213 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Over the last few decades galectin-3, a carbohydrate binding protein, with affinity for N-acetyllactosamine residues, has been unique due to the regulatory roles it performs in processes associated with tumor progression and metastasis such as cell proliferation, homotypic/heterotypic aggregation, dynamic cellular transformation, migration and invasion, survival and apoptosis. 29315388 2018